News

This study highlights upadacitinib’s efficacy across clinical phenotypes for those with atopic dermatitis, noting any differences in response rates among patients.

United Therapeutics’ investigational UKidney is derived from a 10 gene-edited source pig and will be tested in a clinical study of ESRD patients.

This month in review spotlights HCPLive’s coverage of hepatic pipeline news and recent research about MASLD, liver transplant, and alcohol in liver disease.

In this episode, Nada Elbuluk, MD, and Michelle Rodrigues, MBBS, discuss diagnosis and management of pigmentary disorders in skin of color.

This review of January 2025 in dermatology news highlights new developments in the treatment of conditions such as psoriasis, alopecia areata, and atopic dermatitis.

Once-weekly tirzepatide may be an alternative to daily hormone shots in patients with congenital generalized lipodystrophy.

This month in review spotlights HCPLive’s coverage of gastroenterology pipeline news, a feature about gastroparesis and migraine, and recent GI research.

Our top 5 headlines include approvals for a non-opioid pain reliever, the latest indication for semaglutide, positive phase 2 data in MASH, and more.

This FDA News Month in Review provides a round-up of regulatory decisions and submissions from January 2025.

Greater magnesium depletion scores were longitudinally linked to increased risks for all-cause and CVD mortality in patients with MASLD or MetALD.

Awarded to Beacon Therapeutics, RMAT designation allows enhanced communications with the FDA across the development of the investigational gene therapy.

This literature review explored the topic of hidradenitis suppurativa management during pregnancy and lactation, highlighting data available on this topic.

Although FIB-4, ELF, and VCTE LSM performance did not vary significantly by patient characteristics, threshold adjustment was needed.

In this episode, hosts discuss the approval of semaglutide (Ozempic) for reducing the progression of kidney disease in type 2 diabetes.

The FDA approval of suzetrigine, a non-opioid pain signal inhibitor, may help address the needs of patients with moderate-to-severe acute pain.

These data may provide useful information for additional studies on the pathogenesis and treatments of urticaria-related psoriasis.

Garimella describes the overlap between diabetes and kidney disease, explaining the significance of semaglutide’s new indication for these patients.

The American Heart Association’s 2025 statistical update confirms cardiovascular diseases claim more US lives than all forms of cancer and accidental deaths.

Axsome Therapeutics announced that the FDA approved the NDA for AXS-07 to treat acute migraine with or without aura on January 30, 2025.

A study showed that greater total cholesterol and low-density lipoprotein cholesterol were associated with a quicker decline in global cognition.

Merck announced robust efficacy data on the benefit of sotatercept for PAH in the STELLAR and ZENITH studies led to a loss of clinical equipoise in HYPERION.

In this study, several predictive factors for positive alopecia areata outcomes after baricitinib therapy were identified, including female sex and a lower SALT score before treatment.

The rolling NDA submission will include new data from the STARS Extend open-label extension study as well as data from the phase 3 STARS trial.

A study found palliative care for dementia did not improve neuropsychiatric symptoms but reduced emergency visits and hospitalizations over 2 years.

Findings suggest the benefits of combined belatacept and tacrolimus immunosuppression after kidney transplantation for patient and all-cause graft survival.

Frevecitinib is a novel inhaled dry powder therapeutic in development for asthma that remains inadequately controlled by SOC inhaled maintenance therapies.

Results from the Phase 3 LIBerate-HoFH trial found LDL-C responses generally similar between patients treated with lerodalcibep and evolocumab.

In this analysis, investigators explored whether dietary sodium intake was linked with psoriasis and whether any subgroups of patients were more likely to report salt-sensitive psoriasis.